Main page content

Displaying results 1 - 6 of 6
Publication ID: PEP20-02-02-014
Published:

This Advisory is based on TIP 35, Enhancing Motivation for Change in Substance Use Disorder Treatment. It addresses the spirit, application, and fundamentals of motivational interviewing (MI), discusses how practitioners can effectively employ MI in substance use disorder (SUD) treatment, and provides tools that practitioners can use to encourage and promote lasting positive outcomes for their clients.

Publication ID: PEP20-06-04-008
Published:

This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders (SUDs) and TIP 32, Treatment of Adolescents with SUDs. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

Publication ID: SMA16-4979
Published:

This guide offers best practices for treating women living with substance use disorders in co-ed treatment and recovery settings. It highlights the importance of gender differences, cultural sensitivity, and developing healthy relationships.

Publication ID: SMA13-4788
Published:

This quick guide helps administrators of substance use disorder treatment facilities implement programs and services that address the needs of women living with substance use disorders. It addresses patterns of use and the drug screening and treatment needs of women.

Publication ID: SMA13-4353
Published:

This guide helps substance use counselors treat clients with symptoms of depression and substance use conditions. Program administrators will learn how to integrate depression treatment into early drug treatment. The guidelines cover screening, assessment, treatment, counseling, cultural competence, and continuing care.

Publication ID: SMA10-4542
Published:

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.